Busting robustness: Using cancer's greatest strength to our advantage

Future Oncology

Volumn 11, Issue 1, 2015, Pages 73-77

  Westin, Jason R ^a  

^a NONE   (United States)

Author keywords

Cancer; combination therapy; complexity; robustness; scale free networks; small molecule inhibitors; targeted therapy

Indexed keywords

CANCER CELL; CANCER RESEARCH; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; THEORETICAL MODEL; GENETICS; HUMAN; INTERNET; NEOPLASM; PATHOLOGY;

HUMANS; INTERNET; MODELS, THEORETICAL; NEOPLASMS;

EID: 84921047184     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.49     Document Type: Review

References (19)

1. Chapman PB, Hauschild A, Robert C et al. improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
2. Westin JR, Kurzrock R. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol. Cancer Ther. 11(12), 2549-2555 (2012).
3. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85-91 (2002).
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
5. Albert R, Barabási AL. Statistical mechanics of complex networks. Rev. Mod. Physics 74(1), 47-97 (2002).
6. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 406(6794), 378-382 (2000).
7. Newman M, Barabási AL, Watts DJ. The structure and dynamics of networks. Princeton University Press, NJ, USA (2011).
8. Albert R, Jeong H, Barabási AL. Diameter of the world-wide web. Nature 401(6749), 130-131 (1999).
9. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabási AL. Hierarchical organization of modularity in metabolic networks. Science 297(5586), 1551-1555 (2002).
10. Schneeberger A, Nat R, Mercer CH et al. Scale-free networks and sexually transmitted diseases: a description of observed patterns of sexual contacts in Britain and Zimbabwe. Sex. Transm. Dis. 31(6), 380-387 (2004).
11. Barabási AL, Jeong H, Néda Z, Ravasz E, Schubert A, Vicsek T. Evolution of the social network of scientific collaborations. Physica A 311(3-4), 590-614 (2002).
12. Reggiani A, Nijkamp P, Cento A. Connectivity and concentration in airline networks: a complexity analysis of Lufthansa's network. Eur. J. Inf. Syst. 19(4), 449-461 (2010).
13. Margolin AA, Nemenman I, Basso K et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7(Suppl. 1), S7 (2006).
14. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 339(6127), 1546-1558 (2013).
15. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 71(23), 7137-7140 (2011).
16. Kopetz S DJ, Chan E, Hecht JR et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28, 15s (2010).
17. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387), 100-103 (2012).
18. Corcoran RB, Ebi H, Turke AB et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2(3), 227-235 (2012).
19. Mao M, Tian F, Mariadason JM et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res. 19(3), 657-667 (2013).